Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alnylam Pharmaceuticals, Inc.
  6. News
  7. Summary
    ALNY   US02043Q1076

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
127.77 USD   +1.73%
05/25TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-25-2022 10:00 AM
CI
05/24Alnylam Pharmaceuticals' Phase 3 Study Shows Improvement in Exploratory Endpoints in Patients With Rare Genetic Disease PH1
MT
05/24Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Health Care Stocks Decline Pre-Bell Friday

01/21/2022 | 09:18am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ALNYLAM PHARMACEUTICALS, INC. 1.73% 127.77 Delayed Quote.-25.93%
ATHERSYS, INC. 9.22% 0.2108 Delayed Quote.-76.65%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
REGULUS THERAPEUTICS INC. 12.52% 0.31 Delayed Quote.-1.59%
All news about ALNYLAM PHARMACEUTICALS, INC.
05/25TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, M..
CI
05/24Alnylam Pharmaceuticals' Phase 3 Study Shows Improvement in Exploratory Endpoints in Pa..
MT
05/24Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patien..
BU
05/24Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study ..
CI
05/24TRANSCRIPT : Alnylam Pharmaceuticals, Inc. Presents at H.C. Wainwright Global Investment C..
CI
05/23ALNYLAM PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Finan..
AQ
05/23Alnylam Pharmaceuticals Says Vutrisiran Drug Candidate Showed Clinical Benefit to Amylo..
MT
05/23Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Ph..
BU
05/23Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis ..
CI
05/18Alnylam Announces Health Canada Authorization of OXLUMO™ (lumasiran), the First a..
AQ
More news
Analyst Recommendations on ALNYLAM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 1 089 M - -
Net income 2022 -836 M - -
Net cash 2022 1 216 M - -
P/E ratio 2022 -18,9x
Yield 2022 -
Capitalization 15 436 M 15 436 M -
EV / Sales 2022 13,1x
EV / Sales 2023 8,78x
Nbr of Employees 1 665
Free-Float 99,4%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 127,77 $
Average target price 204,23 $
Spread / Average Target 59,8%
EPS Revisions
Managers and Directors
Yvonne L. Greenstreet Chief Executive Officer & Director
Akshay K. Vaishnaw President
Jeffrey V. Poulton Chief Financial Officer & Executive Vice President
Michael W. Bonney Independent Director
Pushkal P. Garg Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
ALNYLAM PHARMACEUTICALS, INC.-25.93%15 436
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478